155 related articles for article (PubMed ID: 23610116)
1. Initial clinical sensitivity and acquired resistance to MET inhibition in MET-mutated papillary renal cell carcinoma.
Diamond JR; Salgia R; Varella-Garcia M; Kanteti R; LoRusso PM; Clark JW; Xu LG; Wilner K; Eckhardt SG; Ching KA; Lira ME; Schoenmakers EF; Christensen JG; Camidge DR
J Clin Oncol; 2013 Jun; 31(16):e254-8. PubMed ID: 23610116
[No Abstract] [Full Text] [Related]
2. Savolitinib for MET-driven papillary renal cell carcinoma.
Gilbert JA
Lancet Oncol; 2017 Aug; 18(8):e440. PubMed ID: 28669737
[No Abstract] [Full Text] [Related]
3. Response to crizotinib in a patient with MET-mutant papillary renal cell cancer after progression on tivantinib.
Stein MN; Hirshfield KM; Zhong H; Singer EA; Ali SM; Ganesan S
Eur Urol; 2015 Feb; 67(2):353-4. PubMed ID: 25457019
[No Abstract] [Full Text] [Related]
4. Molecular and functional characterization of reversible-sunitinib-tolerance state in human renal cell carcinoma.
Zaccagnino A; Vynnytska-Myronovska B; Stöckle M; Junker K
J Cell Mol Med; 2024 May; 28(9):e18329. PubMed ID: 38693863
[TBL] [Abstract][Full Text] [Related]
5. Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial.
Schöffski P; Wozniak A; Escudier B; Rutkowski P; Anthoney A; Bauer S; Sufliarsky J; van Herpen C; Lindner LH; Grünwald V; Zakotnik B; Lerut E; Debiec-Rychter M; Marréaud S; Lia M; Raveloarivahy T; Collette S; Albiges L
Eur J Cancer; 2017 Dec; 87():147-163. PubMed ID: 29149761
[TBL] [Abstract][Full Text] [Related]
6. The MET Inhibitor AZD6094 (Savolitinib, HMPL-504) Induces Regression in Papillary Renal Cell Carcinoma Patient-Derived Xenograft Models.
Schuller AG; Barry ER; Jones RD; Henry RE; Frigault MM; Beran G; Linsenmayer D; Hattersley M; Smith A; Wilson J; Cairo S; Déas O; Nicolle D; Adam A; Zinda M; Reimer C; Fawell SE; Clark EA; D'Cruz CM
Clin Cancer Res; 2015 Jun; 21(12):2811-9. PubMed ID: 25779944
[TBL] [Abstract][Full Text] [Related]
7. Papillary renal cell carcinoma: current progress and future directions.
Twardowski PW; Mack PC; Lara PN
Clin Genitourin Cancer; 2014 Apr; 12(2):74-9. PubMed ID: 24629521
[TBL] [Abstract][Full Text] [Related]
8. Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell Cancer.
Choueiri TK; Plimack E; Arkenau HT; Jonasch E; Heng DYC; Powles T; Frigault MM; Clark EA; Handzel AA; Gardner H; Morgan S; Albiges L; Pal SK
J Clin Oncol; 2017 Sep; 35(26):2993-3001. PubMed ID: 28644771
[TBL] [Abstract][Full Text] [Related]
9. c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations.
Bellon SF; Kaplan-Lefko P; Yang Y; Zhang Y; Moriguchi J; Rex K; Johnson CW; Rose PE; Long AM; O'Connor AB; Gu Y; Coxon A; Kim TS; Tasker A; Burgess TL; Dussault I
J Biol Chem; 2008 Feb; 283(5):2675-83. PubMed ID: 18055465
[TBL] [Abstract][Full Text] [Related]
10. CUL4B promotes aggressive phenotypes of renal cell carcinoma via upregulating c-Met expression.
Chen S; Wang Y; Chen L; Xia Y; Cui J; Wang W; Jiang X; Wang J; Zhu Y; Sun S; Zou Y; Gong Y; Shi B
Int J Biochem Cell Biol; 2021 Jan; 130():105887. PubMed ID: 33227394
[TBL] [Abstract][Full Text] [Related]
11. Chromosomal amplification of leucine-rich repeat kinase-2 (LRRK2) is required for oncogenic MET signaling in papillary renal and thyroid carcinomas.
Looyenga BD; Furge KA; Dykema KJ; Koeman J; Swiatek PJ; Giordano TJ; West AB; Resau JH; Teh BT; MacKeigan JP
Proc Natl Acad Sci U S A; 2011 Jan; 108(4):1439-44. PubMed ID: 21220347
[TBL] [Abstract][Full Text] [Related]
12. Targeting the hepatocyte growth factor/c-Met signaling pathway in renal cell carcinoma.
Harshman LC; Choueiri TK
Cancer J; 2013; 19(4):316-23. PubMed ID: 23867513
[TBL] [Abstract][Full Text] [Related]
13. Germline and somatic c-met mutations in multifocal/bilateral and sporadic papillary renal carcinomas of selected patients.
Salvi A; Marchina E; Benetti A; Grigolato P; De Petro G; Barlati S
Int J Oncol; 2008 Aug; 33(2):271-6. PubMed ID: 18636147
[TBL] [Abstract][Full Text] [Related]
14. Cabozantinib for the treatment of patients with metastatic non-clear cell renal cell carcinoma: A retrospective analysis.
Campbell MT; Bilen MA; Shah AY; Lemke E; Jonasch E; Venkatesan AM; Altinmakas E; Duran C; Msaouel P; Tannir NM
Eur J Cancer; 2018 Nov; 104():188-194. PubMed ID: 30380460
[TBL] [Abstract][Full Text] [Related]
15. Combined Programmed Death-Ligand 1 and MET Inhibition: Has Papillary Renal Cell Carcinoma MET Its Match?
Brown JT; Nazha B; Bilen MA
J Clin Oncol; 2023 May; 41(14):2467-2470. PubMed ID: 36809042
[No Abstract] [Full Text] [Related]
16. Savolitinib Heads for Phase III Trial in PRCC.
Cancer Discov; 2017 Sep; 7(9):OF4. PubMed ID: 28724523
[TBL] [Abstract][Full Text] [Related]
17. [c-MET Oncogene in Renal Cell Carcinomas].
Erlmeier F; Weichert W; Autenrieth M; Ivanyi P; Hartmann A; Steffens S
Aktuelle Urol; 2016 Dec; 47(6):475-479. PubMed ID: 28006830
[TBL] [Abstract][Full Text] [Related]
18. Fishing wild-type sparing inhibitors of proto-oncogene c-met variants in renal cell carcinoma from a curated tyrosine kinase inhibitor pool using analog-sensitive kinase technology.
Wang Z; Jiang M; Feng N; Li C
Biochimie; 2018 Sep; 152():188-197. PubMed ID: 30017898
[TBL] [Abstract][Full Text] [Related]
19. Blocking the autocrine regulatory loop of Gankyrin/STAT3/CCL24/CCR3 impairs the progression and pazopanib resistance of clear cell renal cell carcinoma.
Wang C; Wang Y; Hong T; Cheng B; Gan S; Chen L; Zhang J; Zuo L; Li J; Cui X
Cell Death Dis; 2020 Feb; 11(2):117. PubMed ID: 32051393
[TBL] [Abstract][Full Text] [Related]
20. Combination strategy targeting VEGF and HGF/c-met in human renal cell carcinoma models.
Ciamporcero E; Miles KM; Adelaiye R; Ramakrishnan S; Shen L; Ku S; Pizzimenti S; Sennino B; Barrera G; Pili R
Mol Cancer Ther; 2015 Jan; 14(1):101-10. PubMed ID: 25381264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
